The potential immune-eliciting cancer testis antigens in colorectal cancer

Joanne Ern Chi Soh, Nadiah Abu, A. Rahman A. Jamal

Research output: Contribution to journalReview article

Abstract

The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.

Original languageEnglish
Pages (from-to)1093-1104
Number of pages12
JournalImmunotherapy
Volume10
Issue number12
DOIs
Publication statusPublished - 1 Sep 2018

Fingerprint

Testicular Neoplasms
Colorectal Neoplasms
Antigens
Immunotherapy
Neoplasms
Neoplasm Antigens
Placenta
Testis
Vaccines
Research Personnel

Keywords

  • cancer testis antigen
  • colorectal cancer
  • expression
  • immune responses
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

The potential immune-eliciting cancer testis antigens in colorectal cancer. / Chi Soh, Joanne Ern; Abu, Nadiah; A. Jamal, A. Rahman.

In: Immunotherapy, Vol. 10, No. 12, 01.09.2018, p. 1093-1104.

Research output: Contribution to journalReview article

@article{32709408c5734a70a81ad836b47c5748,
title = "The potential immune-eliciting cancer testis antigens in colorectal cancer",
abstract = "The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.",
keywords = "cancer testis antigen, colorectal cancer, expression, immune responses, immunotherapy",
author = "{Chi Soh}, {Joanne Ern} and Nadiah Abu and {A. Jamal}, {A. Rahman}",
year = "2018",
month = "9",
day = "1",
doi = "10.2217/imt-2018-0044",
language = "English",
volume = "10",
pages = "1093--1104",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - The potential immune-eliciting cancer testis antigens in colorectal cancer

AU - Chi Soh, Joanne Ern

AU - Abu, Nadiah

AU - A. Jamal, A. Rahman

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.

AB - The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.

KW - cancer testis antigen

KW - colorectal cancer

KW - expression

KW - immune responses

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85052975814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052975814&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0044

DO - 10.2217/imt-2018-0044

M3 - Review article

C2 - 30185136

AN - SCOPUS:85052975814

VL - 10

SP - 1093

EP - 1104

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 12

ER -